EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Elettra Merola iD, Chiara Maria Grana

Cancers · 30.05.2023 · 15 (11) · 2975

DOI: 10.3390/cancers15112975 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.05.2023. Verfasst von Elettra Merola und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, G.B. Grassi Hospital (ASL Roma 3), Lido di Ostia, 00122 Rome, Italy. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has emerged as a crucial strategy for treating advanced, unresectable neuroendocrine tumors by administering radiolabeled somatostatin analogs intravenously to target SSTRs. This article will focus on the multidisciplinary theranostic approach, treatment effectiveness (such as response rates and symptom relief), patient outcomes, and toxicity profile of PRRT for NEN patients. We will review the most significant studies, such as the phase III NETTER-1 trial, and discuss promising new radiopharmaceuticals, including alpha-emitting radionuclide-labeled somatostatin analogs and SSTR antagonists.

Schlagwörter

Stichwörter der Autor:innen

neuroendocrine neoplasmspeptide receptor radionuclide therapysomatostatin receptor

Autor:innen und Institutionen

  • Gastroenterology Unit, G.B. Grassi Hospital (ASL Roma 3), Lido di Ostia, 00122 Rome, Italy.
  • Radiometabolic Therapy Unit, Division of Nuclear Medicine, IRCCS European Institute of Oncology, 20141 Milan, Italy.

ORCID-Profile: Elettra Merola

Zitieren

APA

Merola, E., & Grana, C. M. (2023). Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. Cancers, 15(11), 2975. https://doi.org/10.3390/cancers15112975

Vancouver

Merola E, Grana CM. Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. Cancers. 2023;15(11):2975. doi:10.3390/cancers15112975

BibTeX
@article{Merola2023,
  author = {Merola, Elettra and Grana, Chiara Maria},
  title = {Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {11},
  pages = {2975},
  doi = {10.3390/cancers15112975}
}
Kostenlos starten →